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The Effect of Soy Food Intake on Mineral Status
in Premenopausal Women
Ying Zhou, M.S.,1 D. Lee Alekel, Ph.D.,1 Philip M. Dixon, Ph.D.,2
Mark Messina, Ph.D.,3 and Manju B. Reddy, Ph.D.1
Abstract
Background: Soy foods have been substituted for meat in recent years because of proposed health benefits.
Research indicates, however, that soy protein and phytate in soy products inhibit the absorption of divalent
cations.
Methods: Our study was primarily designed to determine the effect of consuming two to three servings per day
of soy foods, providing *19 g protein and *36mg isoflavones, on iron and zinc status in premenopausal
women during a 10-weeks period. As secondary outcomes, we also tested the effect of soy foods on biochemical
markers of bone and thyroid hormones. Nonsmoking women (18–28 years) without chronic disease, anemia,
pregnancy, or irregular menstrual cycles were randomly assigned to either the soy food (SF, n = 31) or animal
food (AF, n = 32) group. Blood and urine samples and 3-day dietary records were collected at baseline and
postintervention.
Results: At baseline, iron and zinc status, bone markers, and thyroid hormones were not different between
groups. After intervention, no significant changes were observed in hemoglobin, transferrin saturation, serum
iron, ferritin, or transferrin receptor (TFR) concentrations. Plasma zinc, but not serum alkaline phosphatase,
significantly decreased in both groups ( - 0.8 lmol/L). The change in bone-specific alkaline phosphatase was
significant between SF (1.5U/L) and AF ( - 0.7U/L) groups. No significant changes were observed in bone
resorption, thyroid-stimulating hormone (TSH), or free thyroxine after soy food intake.
Conclusions: Incorporating *19 g soy protein from soy foods for 10 weeks had no significant effect on iron or
zinc status, bone resorption or formation, or thyroid hormone status in premenopausal women.
Introduction
Soy foods have become popular in the western worldbecause of their proposed health benefits. Soy protein has
been shown to modestly lower blood low-density lipoprotein
cholesterol (LDL-C),1–3 and proposed to reduce bone loss in
postmenopausal women,4,5 prevent breast cancer if exposure
occurs early in life,6–8 and help control diabetes.9,10 Despite
potential benefits, mineral balance may be impaired with soy
consumption because soybeans contain (by weight)*1%–3%
phytic acid,11 which binds minerals such as zinc, iron, and
calcium, thereby decreasing their bioavailability. Although
phytic acid is the major inhibitory factor in soy, the protein
moiety also has been shown to inhibit iron absorption.12
Iron bioavailability has been shown to be extremely poor
not only from soy foods13 but also when soy was mixed with
other foods in single-meal feeding studies.13–15 For example,
iron absorptionwas reduced from 5.5% to 1%, 1.9%, and 0.4%,
respectively, when substituting full fat soy flour, textured soy
flour, or isolated soy protein (ISP by definition is > 90% pro-
tein) for egg albumin in a liquid diet.13 Soy flour has a sig-
nificant amount of iron, and when it was partially substituted
for meat in a meal, the inhibitory effect was shown to be
partially offset by improved availability with meat, as well as
by an increase in the nonheme iron content of themeal.16 Data
on the effect of soy foods or products on iron status with long-
term feeding studies are limited and conflicting. Daily con-
sumption of 40 g/day ISP for 6 months showed no adverse
effect on iron status in perimenopausal women with normal
or borderline slightly compromised iron status at baseline.17
In contrast, however, the same amount of protein for 6 weeks
significantly lowered iron status in postmenopausal women
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who had moderately elevated iron stores, although values
remained within the normal range.18 Recent data showed that
iron is well absorbed from soybean ferritin,19 possibly because
ferritin iron is taken up by a different mechanism than are
other nonheme iron sources.20 Because of this different
mechanism, ferritin iron absorption may be protected from
dietary inhibitors of iron absorption. Although no data are
available, it is possible that ferritin may be degraded during
the processing of soy products, and once the iron is released
from ferritin, phytate may affect its absorption, thus affecting
iron status with soy consumption.
Fewer data are available on the effect of soy foods on zinc
absorption or balance. Soy protein-based diets are generally
considered to have low zinc bioavailability because of their
high phytate/zinc molar ratio.21 When this ratio exceeds 15,
as is the case with soy products, zinc absorption is typically
< 15% compared to 30%–50% with lower ratios.21,22 The in-
hibitory effect of phytate has been shown to be attenuated by
dephytinization of soy protein23–25 and by incorporating milk
and meat into soy-containing meals.26,27 However, there are
limited and conflicting data on the long-term effects of soy on
zinc balance. A soy protein (69 g/day)-based diet for 3months
was reported to cause a negative zinc balance and a reduction
in plasma (25%) and neutrophil (31%) zinc concentrations in a
small group (n = 5) of male subjects.28 However, no effect of
soy protein (0.8 g/kg of body weight) on zinc absorption or
balance was found in another long-term (82 days) feeding
study involving male subjects (n = 6).29
The effect of soy consumption on bone has also beenwidely
studied. Interest in these areas is largely because soy foods are
essentially unique dietary sources of isoflavones. Soy iso-
flavones were shown to attenuate bone loss from the lumbar
spine in perimenopausal women,4 possibly by stimulating
bone formation4,30 or inhibiting bone resorption.30,31 Other
studies, however, have not substantiated these beneficial ef-
fects on bone mineral density (BMD)32,33 or biochemical
markers of bone.33 The effect of soy consumption on thyroid
status is also of interest because four decades ago, goiter was
reported in infants fed soy formula that was not fortified with
iodine.34–36 Perhaps soy isoflavones may impair thyroid
hormone synthesis when iodide intake is inadequate.37 Ad-
ditionally, it is possible that soy consumption could affect
thyroid hormone synthesis by affecting iron status, as thyroid
hormone synthesis involves iron-dependent enzymes (thy-
roid peroxidase and hepatic 5¢-deiodinase).38
Overall, single-meal studies clearly report an inhibitory
effect of ISP on iron and zinc absorption, but it is not clear if
chronic intake of traditional and processed soy foods signifi-
cantly impacts iron and zinc status in healthy young women.
Because young women may have poor dietary habits that
place them at risk for micronutrient deficiencies, we investi-
gated the effect of incorporating commonly consumed soy
foods for 10 weeks on mineral status in young women. As a
secondary outcome of the study, we also assessed the po-
tential effects of soy food intake on biochemical markers of
bone and thyroid hormone status.
Excluded (n=14)
BMI beyond criteria (6)
Work schedule conflict (6)
Irregular menstruation (1)
Soy foods consumed >2 
times/wk (1)
Subjects Responded
N=195
Assessed for Eligibility via Telephone Screening
N=87
Completed Blood Screen and Pregnancy
Test: Randomized to Treatment
N=70
SF Group
n=37
Completed Pre-Baseline Screening:
Initial Eligibility Confirmed
N=73
AF Group
n=33
Excluded (n=3)
Chronic disease (3)
Completed Treatment
n=32
Completed Treatment
n=31
Lost to Follow-up (n=3)
Dropped Out (n=2)
Iron supplement use (1)
Time conflict (1)
Lost to Follow-up (n=2)
FIG. 1. Subject recruitment. AF, animal food; BMI, body mass index; SF, soy food.
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Materials and Methods
Subject selection
We recruited women aged 18–40 years by sending emails
to Iowa State University personnel and posting fliers
throughout the campus. As shown in Figure 1, 195 subjects
initially responded to study postings. Based on our initial
expectation and power calculations, we needed 70 subjects;
thus, we screened only the first 87 of 195 subjects who re-
sponded, anticipating *20% eligibility. Based on the initial
telephone screening of 87 subjects, 74 subjects were eligible
to participate. Women who had chronic disease, gastroin-
testinal problems, or anemia or who were pregnant were
excluded, as were those who smoked cigarettes, had irreg-
ular menstrual cycles (< 24 or > 32 days menstrual cycle), a
body mass index (BMI) £ 18.5 or ‡ 30 kg/m2, or consumed
soy products more than twice per week. Women who met
these criteria and were willing to be randomly assigned to
either the soy food (SF) or animal food (AF) group for 10
weeks were included. Once we confirmed that subjects were
not pregnant (using pregnancy tests) and had normal blood
chemistry profiles, 70 subjects were invited to participate.
Based on our previous study,19 we designed this study with
35 subjects per group to detect a 20% mean change (log scale)
in ferritin (primary outcome) within treatment, with 80%
power at p = 0.05 level of significance. All subjects were in-
structed to discontinue their vitamin/mineral supplement
use. We had a final total sample size of 63 subjects, subse-
quent to losing 2 subjects because of time conflicts or un-
willingness to discontinue mineral supplements, and 5 were
lost to follow-up. We provided verbal explanation and ob-
tained written informed consent from each subject before
baseline data collection. The study protocol, consent forms,
and data collection-related materials were approved by Iowa
State University Human Subjects Review Committee (In-
stitutional Review Board ID 07-505).
Study design
This was a partially controlled feeding study: some meals
were provided on site, and others were consumed at home.
Random numbers were generated using statistical software
(GraphPad Statmate), and 70 subjects were assigned to either
the AF or SF group based on the randomization scheme and
their ID numbers. Each group was provided*two servings/
day of either animal or soy foods during the 10-week study.
Foods provided were considered to be those commonly con-
sumed and widely available. Subjects came to the Nutrition
and Wellness Research Center at Iowa State 3 days per week
(Monday, Wednesday, Friday) to eat their meals and to pick
up the frozen meals to consume at home for the remaining
days. Milk and yogurt to be consumed at home daily were
provided as a part of the intervention meal every day. The
weeklymenu for subjects in each group is presented in Table 1.
The soy protein content in the SF group ranged from 18 to
22 g/day, with an average of 19 g. The isoflavone content
(estimated from the United States Department of Agriculture
[USDA] database and the manufacturers) of soy foods we
provided was approximately 36mg/day. In the meals we
provided, total protein content and energy averaged 27 g and
2240 kJ per day for the AF group and 25 g and 2018 kJ for the
SF group, respectively. Because the majority of subjects were
students and were not available during their spring break, we
provided soy protein (20 g) bars (devoid of whey protein) to
the SF group and whey protein (20 g) bars (devoid of soy
protein) to the AF group for 7 days to ensure reasonable
compliance. Subjects in the SF group were instructed to re-
strict any additional soy foods and to limit animal products to
one serving/day. The AF group was instructed not to con-
sume, in addition to the meals we provided during the study
period, more than one serving/day of animal foods (exclud-
ing dairy). We were unable to use blinding in this study be-
cause it was readily apparent to both the subjects and study
staff which foods were being prepared and served to partic-
ular subjects.
Data collection
Questionnaires were administered to subjects at baseline to
collect information on demographic characteristics, medical
and reproductive history, and soy food intake habits. Prior to
and during the last week of intervention, 3-day dietary intake
records (2 weekdays and 1 weekend) were obtained. We as-
sessed the nutrient intake of subjects from 3-day dietary re-
cords using NutritionistPro (version 2.3.1). At baseline and
postintervention, body weight, standing height (measured at
baseline only), and waist and hip circumferences were mea-
sured by trained staff according to a standard protocol.
Overnight fasting blood samples were drawn by phleboto-
mists, and 24-hour urine samples (instructions provided)
were collected from each subject at baseline and post-
intervention. Aliquots of serum/plasma and urine samples
were stored at - 80C until analysis.
Table 1. Weekly Menu for Subjects in Animal Food
and Soy Food Groups
AF SF
Monday Chili without beans Soy chili
Crackers/peanut butter Crackers/soynut butter
Yogurt Soy yogurt
Tuesday Meat balls Soy meat balls
Pasta with sauce Pasta with sauce
Milk Soy milk
Wednesday Taco with beef Taco with soy
Yogurt Soy yogurt
Thursday Beef Tofu
White rice White rice
Stir fried peas
and carrots
Stir fried peas
and carrots
Milk Soy milk
Friday Burger/bun Soy burger/bun
Milk Soy milk
Saturday Green peas Edamame
White rice White rice
Carrots Carrots
Peanuts Soy nuts
Yogurt Soy yogurt
Sunday Chicken Soy chicken
Pasta/sauce Soy pasta/sauce
Milk Soy milk
Milk and yogurt were always consumed at home; condiments
were provided to subjects at each meal in the research unit.
AF, animal food; SF, soy food; Edamame, young green edible
soybeans.
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Laboratory measurements
A certified clinical laboratory (LabCorp; Kansas City, KS)
performed a general blood chemistry profile (complete blood
count [CBC] with differential, iron status [serum iron, total
iron-binding capacity, Tf saturation]), serum thyroid hor-
mone status (thyroid-stimulating hormone [TSH] and thy-
roxine), and zinc status indicators (plasma and urinary zinc,
serum alkaline phosphatase [ALP]). We measured serum
ferritin using an immunoradiometric kit and Tf receptor (TfR)
using an enzyme-linked immunosorbent assay (ELISA) kit
following the manufacturer’s (Ramco Laboratories) guide-
lines. The TfR-F index was calculated as the ratio of serum TfR
to log-transformed serum ferritin to determine nonanemic
iron deficiency.39 Commercial ELISA kits were used to mea-
sure serum bone-specific ALP (BAP, bone formation marker)
activity (Metra BAP) and serum cross-linked C-terminal
telopeptides of type I collagen (CTx, bone resorption marker)
concentration (serum CrossLaps ELISA) using a microtiter
plate reader (ELx808U with KC Junior software, version
1.14) according to the manufacturer’s guidelines. Urinary
isoflavones were determined using a modified high-
performance liquid chromatography (HPLC) procedure.40
The intra-assay and interassay coefficients of variation
(%), respectively, were 5.3% and 6.0% for ferritin, 4.1% and
11.6% for TfR, 2.1% and 9.5% for BAP, and 1.8% and 7.3%
for CTx.
Statistical analyses
Statistical analyses were performed using SAS version 9.1,
with results considered statistically significant at p£ 0.05. The
normality of data was checked before analysis using the
Kolmogorov-Smirnov test and by examining the distribution
of data using histograms. Descriptive statistics includedmean
(range) for age, height, weight, BMI, waist circumference, hip
circumference, and waist/hip ratio; mean – standard devia-
tion (SD) for hemoglobin, serum iron, and serum ALP;
and median (range) for serum ferritin, TfR, Tf saturation,
plasma and urinary zinc, and all dietary intake variables. For
normally distributed data, an unpaired Student’s t test was
performed for between-group comparisons, and a paired
Student’s t test was used for within-group comparisons. For
data that were not normally distributed, comparisons were
conducted using a Mann-Whitney test between groups and a
Wilcoxon signed-rank test within groups. Samples with se-
rum ferritin values < 1lg/L (n = 5 of 126 measurements) were
assigned a value of 2 lg/L for statistical analysis.
Results
Subject characteristics
A total of 63 subjects completed the 10-week dietary in-
tervention. Table 2 includes the baseline characteristics of
subjects. At baseline, subjects in the two groups did not differ
significantly in age, height, or hip circumference. The signif-
icant difference between the two groups in weight, BMI, and
waist circumferencewas because 1 subject in the AF group fell
beyond our BMI inclusion criterion (33 kg/m2). The majority
of the 63 subjects were Caucasian; 11 were Asian, 2 were of
mixed race, 1 was African American, and 1 was Hispanic/
Latina.
Dietary intake
No significant differences between the groups were found
in total dietary intake of energy, protein, carbohydrate, fat,
iron, zinc, calcium, or vitamin C at baseline and post-
Table 2. Baseline Characteristics of Subjects,
by Treatment Group
Treatment group
AF (n = 31) SF (n = 32)
Age, years 21 (18–27)a 22 (18–28)
Height (m) 1.66 (1.54–1.76) 1.65 (1.54–1.77)
Weight (kg)* 64.0 (51.1–96.2) 60.0 (49.0–76.8)
BMI (kg/m2)* 23.3 (18.5–33.9) 22.0 (18.5–27.2)
Waist circumference (cm)* 72.6 (61.2–98.6) 69.6 (58.7–78.2)
Hip circumference (cm) 100.3 (89.4–123.2) 97.5 (86.4–107.7)
Waist/hip ratio 0.72 (0.63–0.83) 0.71 (0.65–0.77)
Student’s t test was used to compare the differences between
groups for height, body mass index (BMI), and waist hip ratio
because these variables were normally distributed; Mann-Whitney
test was used to perform comparison of age, weight, waist
circumference, and hip circumference between groups.
aMean (minimum–maximum).
*p< 0.05.
Table 3. Total Daily Dietary Intake of Subjects
at Baseline and Postintervention
Treatment group
AF (n = 31) SF (n= 32)
Energy (kJ)
Baseline 6,665 (3,483–10,320)a 6,958 (4,023–10,802)
Postinterventionb 6,866 (4,421–13,083) 7,034 (4,375–9,965)
Protein (g)
Baseline 66 (42–97) 67 (39–109)
Postintervention 69 (42–189) 68 (42–97)
Carbohydrate (g)
Baseline 233 (82–321) 226 (158–414)
Postintervention 231 (134–330) 222 (116–391)
Total fat (g)
Baseline 51 (24–112) 53 (17–100)
Postintervention 57 (31–122) 57 (24–99)
Iron (mg)
Baseline 13.7 (6.8–36.5) 14.0 (7.7–32.8)
Postintervention 14.4 (7.4–31.3)* 14.2 (8.5–31.9)
Zinc (mg)
Baseline 7.8 (3.6–15.9) 8.0 (3.5–17.7)
Postintervention 10.0 (5.3–10.0)*** 9.3 (4.5–13.8)
Calcium (mg)
Baseline 725.6 (285.8–1,803) 827.5 (312.2–1,580)
Postintervention 854.5 (446.5–1,942)** 931.2 (466.6–1,330)
Vitamin C (mg)
Baseline 98.1 (21.4–434.2) 97.0 (10.9–322.1)
Postintervention 51.2 (18.0–129.9)*** 54.6 (14.5–229.0)***
Nonparametric tests were used to compare the difference within
each group or between groups. No significant difference was found
in any dietary factor between groups at baseline and postinterven-
tion.
*p < 0.05; **p < 0.01; ***p < 0.001 indicate differences between base-
line and postintervention values within each group.
aMedian (minimum–maximum).
bPostintervention values reflect total daily intake based on usual
food intake plus the meals provided by the study.
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intervention (Table 3). Although the data are not shown in
Table 3, the soy foods provided to the SF compared to the AF
group apparently contributed to the higher daily intake of
iron (5.2mg vs. 4.0mg), calcium (395mg vs. 319mg), and
vitamin C (6.2mg vs. 5.2mg) but lower intake of zinc (3.2mg
vs 4.1mg). Considering overall dietary intake, however, total
iron ( p= 0.044), zinc p= 0.0035), and calcium p = 0.005) in-
creased significantly from baseline to postintervention in the
AF group. Dietary vitamin C decreased significantly
( p< 0.001) from baseline to postintervention in both groups.
Most subjects met the current Dietary Reference Intake
(DRI)41 for protein (46 g/day) and carbohydrate (130 g/day)
at baseline and postintervention. However, more than half of
the subjects fell below the DRI values for iron (18mg/day),
zinc (8mg/day), and calcium (1000mg/day) at baseline.42,43
In addition, the number of subjects who did not meet the
current DRI for vitamin C (75mg/day) increased from base-
line to postintervention: 12 to 22 in the AF group and 9 to 20 in
the SF group.
Compliance
Because subjects consumed only 3 of 14 meals per week
under our surveillance, compliance for soy food intake was
checked using urinary isoflavone analysis for 6 subjects ran-
domly selected in each group at baseline and postinterven-
tion. There was no significant difference between the two
groups at baseline. As expected, the SF group had a higher
urinary isoflavone excretion than the AF group post-
intervention, indicating compliance to soy food intake. Total
urinary isoflavones increased significantly ( p = 0.016) by 16-
fold (from 0.36 – 0.26 to 5.83 – 4.48mg/L urine) in the SF
group, whereas it decreased by 1.4-fold (not significant, from
2.59 – 4.16 to 1.75 – 3.52mg/L urine) in the AF group. Al-
though our studywas a partially controlled feeding study and
given the approximately 36mg/day of isoflavones con-
sumed, the increase in isoflavone excretionwas comparable to
that of previous studies19,31 in which subjects were exposed to
80mg/day of isoflavones.
Iron status
Iron status at baseline and postintervention is presented in
Table 4. Average hemoglobin concentration was normal for
both groups, and no change was observed after intervention.
The median values for serum iron, ferritin, TfR, and Tf satu-
ration were within the normal range at both time points. No
significant changes were observed in serum iron, Tf satura-
tion, or TfR concentration. The posttreatment values for the
AF and SF groups, respectively (18.8 and 22.5 lg/L for ferritin
and 4.94 and 4.47 for the Tfr-F index), were not significantly
different from their respective baseline values. After inter-
vention, the number of subjects classified as iron deficient
based on a serum ferritin cutoff value of < 15lg/L44 increased
from 10 to 11 in the SF group and remained at 11 in the AF
group. In contrast, based on a TfR cutoff value (> 8.5mg/L) to
Table 4. Iron Status of Subjects by Treatment at Baseline and Postintervention
Treatment group
AF (n = 31) SF (n = 32) Normal range
Hemoglobin (g/L)a 115–150
Baseline 131.9 – 7.6 132.8 – 5.8
Postintervention 133.9 – 6.2 134.5 – 5.8
Change 2.3 – 6.4 1.7 – 4.7
Serum iron (lmol/L)a 35–155
Baseline 17.8 – 7.1 17.0 – 9.2
Postintervention 18.3 – 6.1 16.1 – 7.8
Change 0.6 – 7.9 - 0.9 – 11.7
Transferrin saturation (%)b 15–55
Baseline 27 (10–53) 23 (10–82)
Postintervention 28 (13–48) 24 (10–54)
Change 3 (- 24–23) 2 (- 52–41)
Transferrin receptor (mg/L)b 2.9–8.3
Baseline 6.39 (2.82–10.84) 6.16 (4.27–10.86)
Postintervention 6.18 (3.41–14.81) 6.19 (3.71–14.20)
Change - 0.11 (- 4.37–4.85) - 0.16 (- 2.77–3.62)
Serum ferritin (lg/L)b 12–150
Baseline 21.2 (2–110.8) 23.6 (2.4–77.8)
Postintervention 18.8 (2.0–91.1) 22.5 (2.0–65.7)
Change - 1.4 (- 35.2–26.8) - 2.5 (- 46.7–27.4)
TfR-F indexb < 4.5
Baseline 5.15 (1.84–22.82) 4.86 (2.68–26.65)
Postintervention 4.94 (2.19–20.33) 4.47 (2.92–45.81)
Change - 0.18 (- 17.10–12.55) - 0.13 (- 4.17–19.16)
Student’s t test was used for comparison of hemoglobin because it was normally distributed; nonparametric tests were used for comparison
of other iron indices because they were not normally distributed. No significant difference was found between treatment groups for any
variable at baseline or postintervention.
aMean– standard deviation (SD).
bMedian (minimum–maximum).
TfR-F index, transferria receptor-ferritin index.
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identify tissue iron deficiency, the number declined from 7 to
2 in the AF group and 6 to 3 in the SF group, suggesting
improved iron status in both groups. Similarly, using the TfR-
F index ‡ 4.5 to identify nonanemic iron deficiency,39 the
number of iron-deficient subjects declined from 18 to 14 in the
SF group and from 20 to 18 in the AF group.
Zinc status
The median plasma and urinary zinc concentrations were
within the normal range for both groups before and at the end
of the intervention. As shown in Table 5, plasma zinc de-
creased significantly by 0.8 lmol/L in both groups. The
change in urinary zinc excretion was not significant between
the SF and AF groups. Moreover, the change from baseline to
postintervention in serum ALP was not significant for either
group. Although the postintervention values were signifi-
cantly different ( p= 0.017), the change between the groups
was not significant.
Biochemical markers of bone and thyroid hormones
Based on the purported effect of soy isoflavones on bone, we
assessed BAP andCTx (Fig. 2). Frombaseline to 10weeks, BAP
increased in the SF group (1.5U/L) but decreased in the AF
group (- 0.7U/L), and the change between the two groups
was significantly different ( p= 0.024). However, we found no
significant effect of treatment on CTx. Thyroxine concentra-
tions were not significantly affected by either treatment (1.23–
1.22 ng/dL in the SF group and 1.22–1.20 ng/dL in the AF
group). The TSH concentration declined by 13% in the AF
group ( p= 0.018), whereas no significant change was observed
in the SF group (Fig. 3). The change in TSH (- 0.39 vs. 0.11uIU/
dL) was significantly different between the two groups.
Discussion
Although single-meal studies suggest soy protein inhibits
iron and zinc bioavailability, data from long-term studies are
Table 5. Zinc Status of Subjects at Baseline and Postintervention
Treatment group
AF (n = 31) SF (n = 32) Normal range
Plasma zinc (lmol/L)a 70–100
Baseline 12.2 (9.2–21.7) 12.7 (9.5–22.3)
Postintervention 11.2 (8.0–17.6) 11.7 (8.1–19.7)
Change - 0.8 (- 7.5–7.0)* - 0.8 (- 11.2–5.8)*
Urine zinc (lmol/g creatinine)a 100–900
Baseline 405 (77–1282) 427 (77–1068)
Postintervention 396 (57–1316) 480 (174–1394)
Change - 28 (- 886–745) 8 (- 718–629)
Serum alkaline phosphatase (U/L)b 25–150
Baseline 55.19– 10.8 59.78– 10.86
Postintervention** 53.97– 11.89 61.09– 11.17
Change - 1.23 – 7.24 1.13 – 5.63
Student’s t test was used for comparison of serum alkaline phosphatase because it was normally distributed; nonparametric tests were used
for comparison of serum and urinary zinc because they were not normally distributed.
*Differences between baseline and postintervention within each group: p < 0.05.
**Differences between groups: p< 0.02.
aMedian (minimum–maximum).
bMean– SD.
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FIG. 2. Effect of soy food consumption on biochemical markers of bone. AF, SF. Bone formation and resorption
markers (median + interquartile range) at baseline and postintervention were reflected by (A) bone-specific alkaline phos-
phatase (BAP) and (B) C-terminal telopeptides of type-I-collagen (C-Tx), respectively. Nonparametric tests were performed
for comparison; n = 31 for AF group and n = 32 for SF group. *p< 0.05.
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limited. This 10-week feeding study demonstrated that in-
corporating soy foods as part of the habitual diet had no
detrimental effect on iron or zinc status in young women of
childbearing age. At the end of the study, no significant
changeswere observed inmacronutrient intake, indicating that
subjects adjusted their diets in response to the test meals. Total
iron intake significantly increased only in theAFgroup, despite
the higher iron content of the soy foods vs. animal foods (5.2 vs.
4.0mg) that were provided. Subjects in the AF group likely
consumed fewer animal products before intervention than
during the intervention, thereby contributing to their higher
iron intake. Zinc intake in both groups increased after inter-
vention, but this was significant only in the AF group. Simi-
larly, the significant increase in calcium intake in the AF group
may have been due to the increased dairy product intake
during the study. Although vitamin C intake was reduced in
both groups, we did not expect to document an effect on iron
status, as the vitamin C enhancing effect on nonheme iron
absorption is dampened with a complete diet.45 Because the
study began in February and ended in April, we cannot attri-
bute any differences in dietary intake to seasonal variation.
It is important to investigate the effect of soy consumption
on iron status among women of childbearing age, who are at
risk for iron deficiency because of substantial menstrual losses
and poor dietary habits.46 Based on a hemoglobin cutoff value
of 120 g/L,44 none of the subjects in our study were anemic
either at baseline or at the end of the intervention. Although
serum iron and Tf saturation are widely used in iron defi-
ciency screening, their use is limited by the daily fluctuation of
serum iron.47,48 Recently, the TfR-F index was suggested as a
useful indicator of subclinical iron deficiency in healthy sub-
jects.49,50 If the TfR-F index was used to classify subjects with
nonanemic iron deficiency,39 2 subjects in the AF group and 4
subjects in the SF group who had been iron deficient at
baseline became iron sufficient, showing an improvement in
iron status with either intervention. Overall, we found no
negative effect of soy food intake on iron indices.
Our iron results are consistentwith findings from several but
not all studies. Our sample size of 63 could have detected a 16%
difference (significant) in ferritin between baseline and post-
treatment. However, the 5%–6% decrease we observed in both
groups was not significant. To detect a 5%–6% change in fer-
ritin, we would have needed more than 232 subjects per
treatment, calling into question the biologic relevance of such a
small change. A large scale (1308 men and 1541 women) cross-
sectional study in Chinese adults51 found no significant dif-
ference in mean serum ferritin concentrations across quartiles
of tofu intake. In addition, our previous study also demon-
strated that 40g/day ISP for 24 weeks did not affect iron status
in perimenopausal women (n = 69).17 These results differ,
however, from our subsequent 6-week study involving
postmenopausal women (n= 15), which showed a significant
decrease in Tf saturation (28%) and serum ferritin (30%), as
well as a moderate reduction in serum iron (7%), in response
to the consumption of 40 g/day ISP (40 g/d).18 The discrep-
ancy among these studies may be attributed to differences
in iron status of subjects at baseline, in addition to the amount
of soy protein intake and the duration of intervention. Iron
absorption is typically inversely related to iron stores,52 and
postmenopausal women generally have higher iron stores
than premenopausal or perimenopausal women.53 For ex-
ample, the average serum ferritin concentration in the post-
menopausal women was 65.4ng/mL,18 compared to 27.3 ng/
mL in our premenopausal women. Our current results from
premenopausal women agree with those from the perime-
nopausal women,17 but not from those of the postmeno-
pausal18 women, strongly supporting the hypothesis that
subjects with low iron status have higher absorption than
those with adequate iron status, particularly from foods with
low iron bioavailability.
Zinc deficiency is not common in North America,43 but the
third National Health and Nutrition Examination Survey
(NHANES III) data showed that only 39% of female adoles-
cents met the DRI for zinc.54 In the present study, no subjects
were zinc deficient (based on published values for plasma
zinc < 10.71lmol/L and urinary zinc < 153 lmol/g creati-
nine)55 at baseline, and only 2 subjects, both in the AF group,
fell below these cutoffs after intervention. An 8-week cross-
over study reported a 35% reduction in zinc absorption and a
5% decrease in plasma zinc in women (n = 22) who consumed
lacto-ovovegetarian diets.56 Our study also showed a 6% re-
duction ( p= 0.037) in plasma zinc concentration, but the re-
duction was not specific to soy feeding, as a similar reduction
was noted also in the AF group.We expected parallel changes
in both groups because the zinc content of the test meals we
provided was similar for both the AF (5.8mg/day) and SF
(5.6mg/days) groups. However, it was surprising that plas-
ma zinc declined by 7% ( p= 0.048) in the AF group despite a
significant increase in total zinc intake (7.8–10.0mg/day).
Plasma zinc is a relatively insensitive indicator of zinc status,
except with severe zinc deficiency, although it is widely used
as a screening test. Plasma zinc is generally stable but de-
creases with several weeks of severe dietary restriction, after
tissue zinc has been depleted. Thus, plasma zinc poorly re-
flects tissue zinc status and should not be used alone to
identify marginal zinc deficiency.57 More importantly, this
modest reduction was noted in both groups, despite im-
provement in dietary zinc intake. In contrast to the current
results, in a small feeding study involvingmales (n=5), 69g/day
soy protein for 3 months caused a more marked reduction
(25%) in plasma zinc and caused negative zinc balance.28
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FIG. 3. Effect of soy food consumption on thyroid-
stimulating hormone (TSH). AF, SF. TSH at
baseline and postintervention (mean – SEM). Comparisons
determined using Student’s t test to examine the difference
within group and between groups; n= 31 for AF group and
n = 32 for SF group. *p < 0.05, #p < 0.02.
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Further, unlike plasma zinc, we did not observe a reduction in
urinary zinc excretion, likely due to thewide variability in this
measure. Moreover, the minor change in serum ALP activity
from base to postintervention was not different between the
groups and would not raise any concern clinically.
Because of the high phytate content of soy foods, we ex-
pected to document a negative effect of soy food intake on
iron and zinc status, but the results of this study did not
support our hypothesis. However, we cannot rule out the
potential confounding effect of other phytate-containing
foods on mineral status. This illustrates a limitation of this
partially controlled feeding study, in that it would have been
nearly impossible to control for phytate intake because phy-
tate is ubiquitous in the food supply. Based on our dietary
analysis (Table 3), however, there was no difference in mac-
ronutrient intake between treatment groups either at baseline
or at posttreatment, suggesting that confounding with phy-
tate intake should not have been an issue. In addition, mac-
ronutrient intakes were not significantly altered from baseline
within each treatment group. This study was realistic in that
we determined whether habitual soy-based diets would exert
any effect on mineral status rather than controlling 100% of
the subjects’ dietary intake.
We examined the effect of soy foods on biochemical
markers of bone turnover because of speculation that soy
isoflavones, similar to estrogen, might inhibit bone resorp-
tion30,31 and enhance calcium absorption58 and, hence, might
maintain BMD.4,5 Moreover, calcium intake is less in young
adults compared to adolescents because of their lower
milk consumption.59 Our study was not of sufficient dura-
tion to examine BMD, nor could we link the biochemical
markers to osteoporotic risk. Some4,60,61 but not all31,33 hu-
man studies have reported that soy isoflavones decreased
bone resorption or increased bone formation markers, yet
these changes were very modest and not likely to be clini-
cally relevant. We did not find significance within-group
changes in bone formation or resorption markers, perhaps
because these women were not estrogen deficient. Never-
theless, we did note a significant difference in the change in
serum BAP between groups, suggesting that soy foods
might exert either a modest beneficial effect or at least not a
detrimental effect on bone formation.4 In addition, we found
no evidence that soy foods negatively affected serum TSH or
thyroxine concentrations, consistent with essentially all data
on this subject.62 The significant decline in TSH in the AF
group may have indicated an improvement in thyroid hor-
mone status, perhaps because of the increased consumption
of dairy products, a good source of dietary iodine in the
United States.63
Conclusion
We found no detrimental effect in iron or zinc status in
premenopausal womenwhenmoderate amounts of soy foods
are incorporated into their regular diet. Further, we noted no
treatment effect on the biochemical markers of bone or on
thyroid hormone status in this study. Given that this was a
partially controlled feeding study, we designed it to address
the effect of a realistic intake of soy foods on mineral status.
Our results will help provide dietary recommendations for
soy food intake in the age group that is vulnerable to micro-
nutrient deficiency.
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